Efficacy and tolerability of blonanserin in the patients with schizophrenia: A randomized, double-blind, risperidone-compared trial

Clinical Neuropharmacology

Volumn 33, Issue 4, 2010, Pages 169-175

  Yang, Jaewon ^a   Bahk, Won Myong ^b   Cho, Hyun Sang ^c   Jeon, Yang Whan ^d   Jon, Duk In ^e   Jung, Hee Yeon ^f   Kim, Chan Hyung ^g   Kim, Hee Cheol ^h   Kim, Yong Ku ⁱ   Kim, Young Hoon ^j   Kwon, Jun Soo ^k   Lee, Sang Yeol ^l   Lee, Seung Hwan ^j   Yi, Jung Seo ^e   Yoon, Bo Hyun ^m   Kim, Seung Hyun ^a  

^a Korea University College of Medicine   (South Korea)

^b ST MARY S HOSPITAL   (United Kingdom)

^c Yonsei University College of Medicine   (South Korea)

^d Our Lady of Mercy Hospital   (Australia)

^e Hallym University   (South Korea)

^f Seoul National University   (South Korea)

^g Yonsei University College of Medicine   (South Korea)

^h Dongsan Medical Center   (South Korea)

ⁱ Korea University   (South Korea)

^j Inje University College of Medicine   (South Korea)

^k Seoul National University Hospital   (South Korea)

^l Wonkwang University Hospital   (South Korea)

^m Naju National Hospital   (South Korea)

more..

Author keywords

blonanserin; efficacy; schizophrenia; tolerability

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BLONANSERIN; PLACEBO; PROLACTIN; RISPERIDONE;

ADULT; AKATHISIA; ARTICLE; BRADYKINESIA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSARTHRIA; DYSTONIA; FEMALE; GAIT DISORDER; HAND TREMOR; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE RIGIDITY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; TREMOR;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERPROLACTINEMIA; MALE; MIDDLE AGED; PIPERAZINES; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; WEIGHT GAIN; YOUNG ADULT;

EID: 77955141217     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181dcda50     Document Type: Article

References (25)

1. Nagai T, Noda Y, Une T, et al. Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in mice. Neuroreport 2003;14:269-272.
2. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 1963;20:140-144.
3. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223.
4. Potkin SG, Litman RE, Torres R, et al. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol 2008;28:S4-S11.
5. Noda Y, Kurumiya S, Miura Y, et al. Comparative study of 2-(4-ethyl-1-piperazinyl)-4-(fluorophenyl)-5,6,7,8,9, 10-hexahydrocycloocta[b] pyridine (AD-5423) and haloperidol for their pharmacological activities related to antipsychotic efficacy and/or adverse side-effects. J Pharmacol Exp Ther 1993;265:745-751.
6. Oka M, Noda Y, Ochi Y, et al. Pharmacological profile ofAD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. JPharmacol Exp Ther 1993;264:158-165.
7. Kinoshita T. Long-term clinical study of blonanserin for schizophrenia (Japan-wide study). Jpn J Clin Psychopharmacol 2008;11:135-153.
8. Murasaki M. Long-term clinical study of blonanserin for schizophrenia (Kanagawa Region Clinical Psychopharmacology Study Group). Jpn J Clin Psychopharmacol 2007;10:2241-2257.
9. Murasaki M. Clinical evaluation of blonanserin for schizophrenia: a double-blind trial comparing blonanserin with haloperidol. Jpn J Clin Psychopharmacol 2007;10:2059-2079.
10. Mima T, Miura S, et al. Phase III Clinical study of AD-5423: Double-blind, confirmatory study in patients with schizophrenia. Dainippon Pharma Co. Ltd.; 2005.
11. Yi J-S, Ahn YM, Shin H-K, et al. Reliability and validity of the Korean version of the Positive and Negative Syndrome Scale. J Korean Neuropsychaitr Assoc 2001;40:1090-1105.
12. Garcia E, Robert M, Peris F, et al. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study. CNSDrugs 2009;23:615-625.
13. Meltzer HY, Fatemi SH. Schizophrenia. In: Current Diagnosis and Treatment in Psychiatry. New York:McGraw-Hill; 2000:206-277.
14. Kim M-K, Lee B-K, Jeon Y-W. Reliability of Korean Brief Psychiatric Rating Scale (BPRS)-comparison of interrater reliability between the two rating methods and correlation of BPRS and Scl-90 self-report test. Han'gug Simlihag Hoeji Imsang 2003;22:685-698.
15. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799-812.
16. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976: 218-222.
17. Kim JH, Jung HY, Kang UG, Jeong SH, et al. Metric characteristics of the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS): a practical rating scale for drug-induced movement disorders. Mov Dis 2002;17:1354-1359.
18. Oka T, Hamamura T, Lee Y, et al. Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain. Life Sci 2004;76:225-237.
19. Addington DE, Pantelis C, Dineen M, et al. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry 2004;65:1624-1633.
20. Glick ID, Mankoski R, Eudicone JM, et al. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials. J Affect Disord 2009;115:18-26.
21. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-136.
22. Martin JL, Perez V, Sacristan M, et al. Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia. Eur Psychiatry 2006;21:11-20.
23. Scheen AJ, De Hert MA. Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab 2007;33:169-175.
24. Ramaswamy K, Masand PS, Nasrallah HA. Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies. Ann Clin Psychiatry 2006;18:183-194.
25. Glassman AH. Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry 2005;66(Suppl 6):5-10.